Skip to main content

Market Overview

Bernie Sanders: 'Ozempic Will Likely Become One Of The Best-Selling Pharmaceutical Products In History' — Americans Shouldn't Pay 10-15X More

Share:
Bernie Sanders: 'Ozempic Will Likely Become One Of The Best-Selling Pharmaceutical Products In History' — Americans Shouldn't Pay 10-15X More

In a recent tweet, Bernie Sanders (I-Vt.) criticized the pricing of a popular diabetes drug, Ozempic, and its manufacturer, Novo Nordisk A/S (NYSE:NVO).

What Happened: Sanders took to X, formerly Twitter, on Wednesday to express his concerns about the pricing of Ozempic. He suggested that the drug’s manufacturer, Novo Nordisk, will make billions of dollars from U.S. consumers annually, charging them 10-15 times more than people in other countries.


“Ozempic will likely become one of the best-selling pharmaceutical products in history. Its manufacturer, Novo Nordisk, will make billions of dollars from U.S. consumers every year. Americans should not be charged 10-15x more for this drug than people in other countries,” Sanders said.

See Also: A Month Back Elon Musk Said Boeing Was Weighed Down By ‘Too Many Non-Technical Managers.’ Fast-Forward, The Plane Maker Has Stranded 2 Astronauts In Space: They Have Only 27 Days Of Fuel Left, Here’s What Happens Next

Why It Matters: This isn’t the first time Sanders has taken a stand against the high cost of Ozempic. In March, he criticized the “outrageous” prices of the drug and considered holding hearings on the issue. Sanders, who chairs the Senate Health, Education, Labor, and Pensions (HELP) Committee, expressed concerns about the high cost of Ozempic, which is sometimes used controversially for weight loss by suppressing appetite.

Novo Nordisk CEO, Lars Fruergaard Jørgensen, agreed to testify before the Senate after Sanders threatened to subpoena the company over its pricing of Ozempic and the obesity drug Wegovy. This agreement followed a public dispute over scheduling a hearing, with Sanders’ team claiming Novo was uncooperative, while the company said it was willing to testify.

Price Action: On Wednesday, Novo Nordisk shares closed 2.2% lower at $143.67 in the regular session, according to Benzinga Pro data.

Photo by Joseph Sohm on Shutterstock

Read Next: Hillary Clinton Offers Advice To Biden Ahead Of Presidential Debate: ‘It’s A Waste Of Time To Try To Refute Mr. Trump’s Arguments’

This story was generated using Benzinga Neuro and edited by Shivdeep Dhaliwal

 

Related Articles (NVO)

View Comments and Join the Discussion!

Posted-In: Bernie Sanders Diabetes GLP GLP-1 drugsNews Health Care Politics General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com